XBiotech, the developer of True Human therapeutic antibodies headquartered in Austin, Texas, says Trey Benson has joined the company as Commercial Head.
Benson has more than 20 years of global healthcare experience, with more than 16 involved in marketing and commercial development in the pharmaceutical industry, in both established and start-up organisations.
Reporting to XBiotech Founder, President and Chief Executive John Simard, Benson will lead the commercial development for XBiotech’s True Human antibody therapies, including Xilonix, the firm’s lead candidate currently in late-stage development for the treatment of advanced colorectal cancer.
Benson’s extensive experience has seen him serve as Vice President of Marketing at Edgemont Pharmaceuticals, as well as nine years at Xenoport, where he moved from Senior Director, Strategic Product Planning to Executive Director, Commercial Development and on to Vice President of Marketing and Commercial Development. At Xenoport, Benson led all Horizant (gabapentin enacarbil) promotional activities, including launch planning in co-promotion collaboration with GSK, building the commercial organisation and marketing team, and being responsible for sales performance.
He began his career with Abbott Laboratories and Eli Lilly.
